XETR
BAYN
Market cap42bUSD
Jun 18, Last price
37.15EUR
1D
-1.56%
1Q
-3.23%
Jan 2017
-61.79%
Name
Bayer AG
Chart & Performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Bayer AG, a global life sciences enterprise operating through its various subsidiaries, strategically organizes its operations into three key divisions: Pharmaceuticals, Consumer Health, and Crop Science. The Pharmaceuticals division primarily focuses on prescription medications, predominantly addressing cardiovascular conditions and women's health. Additionally, it develops specialized therapies in areas like oncology, hematology, and ophthalmology, alongside offering diagnostic imaging equipment, contrast agents, and pioneering cell and gene therapies. Within the Consumer Health segment, the company provides a range of over-the-counter (OTC) remedies, medical devices, skincare products with medicinal properties, nutritional supplements, and general self-care solutions. These offerings cater to diverse health needs such as dermatological issues, dietary support, pain management, cardiovascular risk reduction, digestive well-being, allergy relief, and common cold and cough symptoms. The Crop Science segment is dedicated to agricultural innovation, supplying chemical and biological crop protection agents, enhanced plant varieties, seeds, digital tools, and solutions for pest and weed control. It also delivers crucial customer services to the farming community and is involved in the breeding, propagation, and processing of seeds, including specialized seed treatments. Bayer actively engages in numerous collaborations to advance its research and development pipeline. Key partnerships include an agreement with MD Anderson Cancer Center for developing oncology drugs, a research and license agreement with Dewpoint Therapeutics, Inc. focused on new treatments for cardiovascular and gynecological conditions, and collaborations with Exscientia Ltd, Foundation Medicine Inc., and Evotec AG. Further alliances involve a research collaboration with Arvinas Inc., a strategic partnership with the University of Oxford for novel gynecological therapies, and a joint effort with Kyoto University to identify potential new drugs for pulmonary diseases. Its wide array of products reaches consumers through various channels, including wholesalers, pharmacies and pharmacy chains, supermarkets, online platforms, other retail outlets, hospitals, and direct sales to farmers. Established in 1863, the company's headquarters are situated in Leverkusen, Germany.
Valuation
Title EUR in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||